# Xintela > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/xintela). ## Overview Xintela is a Swedish clinical-stage biopharma company based in Lund that develops stem cell therapies and targeted cancer therapies built around the cell-surface marker integrin α10β1. Its business includes the XSTEM stem cell platform, an in-house GMP manufacturing facility, and Targinta AB, a wholly owned subsidiary focused on antibody-based oncology programs. ## Products & services • XSTEM stem cell therapy platform • GMP manufacturing of cell therapies • TARG9 antibody-drug conjugate (ADC) • TARG10 function-blocking antibody • EQSTEM veterinary stem cell product • Cell therapy process development services - **Stem cell therapy products** (45%) — XSTEM and related stem cell treatments for human regenerative medicine. - **GMP manufacturing and process development** (30%) — In-house production and development services for cell-based products. - **Oncology antibodies** (15%) — Targinta's preclinical antibody programs targeting integrin α10β1 in cancer. - **Veterinary stem cell products** (10%) — EQSTEM and other animal stem cell programs for equine and veterinary uses. - XSTEM stem cell therapy platform - GMP manufacturing of cell therapies - TARG9 antibody-drug conjugate (ADC) - TARG10 function-blocking antibody - EQSTEM veterinary stem cell product - Cell therapy process development services ## Customers Xintela sells into clinical development, research, and collaboration settings rather than mass commercial healthcare markets. Its direct customers and partners include hospitals, research institutions, biotech collaborators, and potential licensees that need stem cell products, GMP manufacturing, or development rights. In veterinary applications, the customer base extends to animal health partners and product developers. - **Clinical development partners** (primary) — Buy or collaborate on XSTEM and oncology programs for human clinical and preclinical development. - **GMP service customers** (primary) — Use Xintela's facility for process development and manufacturing of cell-based products. - **Licensees and strategic partners** (secondary) — Acquire rights to Xintela's stem cell or antibody technology for commercialization. - **Veterinary developers** (secondary) — Work on EQSTEM and other animal stem cell products for equine indications. - Clinical trial partners using XSTEM in human studies - Hospitals and care providers involved in cell therapy studies - Biotech and pharma partners seeking licensing or co-development - Research institutions needing GMP process development - Veterinary partners developing EQSTEM for horses and other animals ## Geography Xintela is headquartered and operates from Lund, Sweden, with its core laboratory and GMP activities based at Medicon Village. Its clinical and partnering footprint extends beyond Sweden through studies and collaborations in Australia, the United States, and other international markets. Geography matters because the company depends on cross-border clinical development, regulatory pathways, and partner access rather than a single domestic sales market. - Headquartered in Lund, Sweden - Core operations at Medicon Village in Lund - Clinical study activity in Australia - Oncology collaboration in New York, USA - Partnering and licensing are international in scope ## Strategy Xintela's strategy is to advance XSTEM toward approved therapy status through clinical data, strategic partnerships, and commercialization agreements. At the same time, it uses its GMP facility to generate service revenue and build manufacturing capabilities that can support both internal programs and external cell therapy projects. - **Secure a strategic partner for XSTEM** (short-term) — Partnerships can accelerate regulatory, clinical, and commercial progress for the lead stem cell asset. - **Grow GMP service revenue** (short-term) — External manufacturing and process development can help fund operations and validate the platform. - **Advance oncology programs in Targinta** (medium-term) — The antibody pipeline broadens the technology base and creates optionality beyond stem cells. - **Extend the platform into veterinary medicine** (medium-term) — Animal health programs can create additional licensing and manufacturing opportunities. - Advance XSTEM through clinical development and partner support - Seek licensing or commercialization deals for osteoarthritis - Monetize GMP capacity through external process development work - Develop Targinta's oncology antibodies with research partners - Expand veterinary applications through EQSTEM collaborations ## Risks Xintela faces the typical risks of a clinical-stage biotech company: product candidates may fail in development, regulatory pathways may be longer than expected, and commercial adoption may not materialize. The company also depends on external financing and partner support, while its GMP and collaboration model creates execution risk around manufacturing quality, study timelines, and contract revenue. - **Product development failure** [critical] — XSTEM, TARG9, and TARG10 are still in development and may never reach market. - **Financing risk** [high] — The company relies on equity, loans, grants, and collaboration income to fund operations. - **Regulatory and clinical risk** [high] — Cell therapies and antibodies require successful trials and approvals across jurisdictions. - **Partner concentration and execution risk** [medium] — Service revenue and development milestones depend on a limited number of collaborations. - **Patent and IP risk** [medium] — The business depends on protecting integrin α10β1-based technology and related families. - Clinical programs may fail to show sufficient safety or efficacy - Regulatory approval timelines are uncertain and can be lengthy - Capital needs are ongoing because development is pre-commercial - Partnering and licensing deals may take longer than expected - GMP execution or quality issues could disrupt service revenue ## Accounting Xintela's reported numbers are shaped by development-stage accounting, where most spending is expensed as research and development rather than capitalized. Revenue can be lumpy because it comes from collaborations, service assignments, and milestone-type arrangements, while leases, patents, and any future impairment testing can also affect reported results. - **Research and development expense recognition** - **Collaboration and service revenue timing** - **Intangible assets and patent portfolio** - **Lease accounting** - **Going-concern and financing assumptions** - R&D is expensed as incurred, driving large operating losses - Collaboration and service revenue may be uneven quarter to quarter - Lease accounting affects premises costs for the Lund facility - Patent and IP assets require judgment on capitalization and impairment - Loan and equity financing affects cash flow and dilution analysis --- *Last updated: 2026-08-11T04:04:57.142384+00:00*